Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri® in patients with relapsing remitting multiple sclerosis: Primary data from the Phase III Antelope study

The requested reference [13cb904dc562a5dfb008e961f85b96bfe9ae805a] no longer exists in our database. It has been replaced by the current reference: [c67c4d86e023960b324671a7c74a9a936bb57ef4]

Authors
Category Primary study
JournalNeurology
Year 2022
This article has no abstract
Epistemonikos ID: 906e38cc39ac70eacbc6e55b5adc15a26478cc41
First added on: Feb 14, 2025